Botulinum Toxins A and B – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers specific botulinum toxin products (Botox, Dysport, Xeomin, Daxxify, Myobloc) for their proven neurologic, urologic, gastrointestinal and movement‑disorder indications (Botox also for chronic migraine prophylaxis when diagnostic criteria are met) and excludes numerous unproven/off‑label uses and cosmetic treatments (hyperhidrosis coverage depends on the member’s benefit plan). Key requirements: documented diagnosis, prescriber attestation that dosing follows FDA labeling or published clinical evidence, administrations no more often than every 12 weeks, product‑specific age/previous‑treatment limits and condition‑specific documentation (e.g., headache diaries, bladder treatment failure to anticholinergics, functional scales); all products carry an FDA boxed warning for distant spread of toxin effect.

"Dysport (abobotulinumtoxinA) proven for: Achalasia"